YARW Yarrow Bioscience, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1566044 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.1%
TTM net income YoY-35.6%
TTM EPS YoY-1,140.7%
Revenue 3-yr CAGR-12.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,949.6%
Net margin-8,097.7%
FCF margin—
EBITDA margin—
Returns
ROE-67.8%
ROA-58.7%
ROIC (approx.)-108.4%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | $97,000 | $86,000 | $69,000 | $202,000 | $84,000 | $121,000 | $198,000 |
| R&D expense | $5.28M | $788,000 | $817,000 | $4.88M | $6.12M | $9.68M | $10.25M | $7.31M |
| SG&A expense | $5.47M | $2.41M | $3.08M | $2.73M | $3.27M | $3.17M | $2.96M | $3.29M |
| Operating income | -$10.74M | -$3.10M | -$3.82M | -$7.54M | -$9.20M | -$12.77M | -$13.09M | -$10.40M |
| Pretax income | — | -$2.90M | -$3.58M | -$5.75M | -$8.60M | -$12.01M | -$12.16M | -$9.39M |
| Income tax | — | $0 | $0 | $0 | $0 | $4,000 | $0 | $0 |
| Net income | -$9.72M | -$6.51M | -$2.75M | -$5.75M | -$8.61M | -$12.02M | -$12.16M | -$9.41M |
| EBITDA | -$10.75M | -$3.10M | -$3.81M | -$7.53M | -$9.19M | — | — | -$10.40M |
| EPS (basic) | -0.43 | -3.51 | -0.08 | -6.73 | -0.20 | — | -0.29 | -0.22 |
| EPS (diluted) | -0.43 | -3.51 | -0.08 | -6.73 | -0.20 | — | -0.29 | -0.22 |
| Weighted avg. shares (diluted) | 22.59M | 858,000 | 42.77M | 855,000 | 42.67M | — | 42.59M | 42.59M |
| Banking | ||||||||
| Net interest income | $925,000 | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $268.86M | $22.93M | $24.63M | $22.05M | $28.21M | $19.93M | $16.27M | $29.61M |
| Short-term investments | — | $0 | $297,000 | $17.60M | $22.06M | $41.59M | $53.91M | $48.49M |
| Current assets | $273.96M | $23.53M | $25.79M | $44.34M | $54.91M | $64.44M | $73.53M | $83.78M |
| PP&E, net | $72,000 | $78,000 | $84,000 | $102,000 | $107,000 | $113,000 | — | — |
| Total assets | $274.03M | $23.60M | $25.87M | $44.72M | $56.42M | $66.91M | $76.20M | $86.65M |
| Current liabilities | $6.51M | $1.54M | $1.24M | $5.84M | $12.29M | $14.82M | $12.66M | $11.75M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $6.51M | $1.54M | $1.24M | $5.84M | $12.29M | $14.82M | $12.66M | $11.78M |
| Shareholders' equity | $267.52M | -$79.43M | -$73.43M | $38.88M | $44.13M | $52.09M | $63.54M | $74.87M |
| Net debt | -$268.86M | -$22.93M | -$24.63M | -$22.05M | -$28.21M | -$19.93M | -$16.27M | -$29.61M |
| Shares outstanding | 11.47M | 668,327 | 33.35M | 19.77M | 15.96M | 14.83M | 14.75M | 14.54M |
| Cash flow statement | ||||||||
| Operating cash flow | -$89.96M | -$1.99M | -$4.08M | -$10.80M | -$11.46M | -$9.00M | -$8.51M | -$8.48M |
| Investing cash flow | — | $300,000 | $4.70M | $4.67M | $19.83M | $12.74M | -$4.82M | $19.02M |
| Financing cash flow | $265.03M | -$14,000 | -$15,000 | -$34,000 | -$87,000 | -$132,000 | -$2,000 | -$3,000 |
| Depreciation & amortization | -$8,000 | $6,000 | $6,000 | $12,000 | $6,000 | — | — | $0 |
| Stock-based compensation | $705,000 | $436,000 | $474,000 | $529,000 | $763,000 | $699,000 | $734,000 | $885,000 |
Free plan shows the latest 8 periods; Pro shows all 41 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.